晨会纪要（R3） 晨会纪要 2026 年 03 月 03 日 | 市场数据 | | | | --- | --- | --- | | 指数名称 | 收盘 | 涨跌% | | 上证指数 | 4182.59 | 0.47 | | 深证成指 | 14465.79 | -0.20 | | 创业板指 | 3294.16 | -0.49 | | 科创 50 | 1464.77 | -1.56 | | 北证 50 | 1475.73 | -3.99 | | 沪深 300 | 4728.67 | 0.38 | 上证指数-沪深 300 走势图 -8% 2% 12% 22% 32% 2025-03 2025-06 2025-09 2025-12 上证指数 沪深300 | 黄红卫 | 分析师 | | --- | --- | | 执业证书编号:S0530519010001 | | | huanghongwei@hnchasing.com | | | 陈郁双 | 分析师 | | 执业证书编号:S0530524110001 | | | chenyushuang@hnchasing.com | | 晨会聚焦 一、财信研究观点 【市场策略】三 ...

获得受理的公告 证券代码：000661 证券简称：长春高新 公告编号：2026-011 长春高新技术产业（集团）股份有限公司 关于子公司 GenSci161 注射液境内生产药品注册临床试验申请 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股 子公司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品 监督管理局核准签发的《受理通知书》，金赛药业 GenSci161 注射液的境内生产 药品注册临床试验申请获得受理，现将有关情况公告如下： 一、药品的基本情况 产品名称：GenSci161 注射液 申请事项：境内生产药品注册临床试验 受理号：CXSL2600282、CXSL2600283 申请人：长春金赛药业有限责任公司 审批结论：经审查，决定予以受理 适应症：用于子宫内膜异位症和化脓性汗腺炎 二、药品的其它情况 GenSci161 注射液是金赛药业自主研发的一款治疗用生物制品 1 类药物，拟 用于治疗子宫内膜异位症和化脓性汗腺炎。 子宫内膜异位症是女性常见慢性系统性炎症性疾病，发病率约 ...

证券日报网讯 2月27日，长春高新在互动平台回答投资者提问时表示，公司目前获批临床的适应症是用 于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增 生症、特发性的原因导致的儿童小阴茎，未来如有其他达到披露标准的新情况，公司将按照法律法规要 求履行相应的披露义务。 （文章来源：证券日报） ...

证券日报网讯2月27日，长春高新（000661）在互动平台回答投资者提问时表示，公司员工情况会按照 法律法规要求在定期报告相应章节具体列示，具体请关注定期报告相关内容。 ...

证券之星消息，2月27日，生物经济（970038）指数报收于2178.02点，跌0.57%，成交7.9亿元，换手率 0.06%。当日该指数成份股中，上涨的有33家，英科医疗以5.08%的涨幅领涨，下跌的有12家，长春高 新以2.77%的跌幅领跌。 资金流向方面，生物经济（970038）指数成份股当日主力资金净流出合计2.53亿元，游资资金净流出合 计2.08亿元，散户资金净流入合计4.61亿元。成份股资金流向详情见下表： 生物经济（970038）指数十大成份股详情如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the clinical trial application of GenSci141 ointment, the world's first specific treatment for children's micropenis, marking a historic breakthrough in a long-neglected area of standard drug treatment [2][3]. Company Summary - The approval of GenSci141 ointment represents a shift from empirical medication to precision treatment for children's micropenis, providing the first clinically validated standard treatment option [3]. - The stock price of Changchun High-tech reacted strongly to the news, closing at 97.26 yuan per share on February 25, and reaching a peak of 108 yuan on February 26, with a cumulative increase of over 12% in two days, pushing the total market value beyond 40 billion yuan [2]. - The company maintains a cautious stance regarding the project, indicating that it is still in the early stages and that the drug has only received approval for clinical trials, with no confirmed timeline for market launch [3][4]. Industry Summary - The biopharmaceutical industry is a core component of China's strategic emerging industries, essential for public health, technological innovation, and enhancing the country's self-sufficiency in medicine [4]. - The Chinese biopharmaceutical market is projected to grow from 345.7 billion yuan in 2020 to 524.2 billion yuan by 2024, with expectations to exceed 800 billion yuan by 2028, maintaining an annual growth rate of 10%-12% [4]. - The industry value chain consists of upstream raw materials, midstream research and production, and downstream distribution and consumption, with the midstream segment holding the highest profit margins due to its technological barriers [6][8].

【#长春高新回应儿童小阴茎专用药获批#：上市至少要三年】#儿童小阴茎专用药上市至少三年#27日， 长春高新股价开盘走低，一度跌超4%。截至发稿，长春高新报95.88元/股。对于股价走势，@中新经纬 以投资者身份致电长春高新证券部，一位工作人员回应称，"股价涨跌背后，没有特殊原因。"2月24 日，长春高新发布公告称，子公司金赛药业GenSci141软膏境内生产药品注册临床试验申请获得批准。 该药品用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上 腺皮质增生症、特发性原因导致的儿童小阴茎。对于GenSci141软膏的研发进展，上述工作人员回应 称，基于对药物研发的通常理解，一切顺利的情况下，从临床获批到上市的周期，至少也要三年。但每 一个试验阶段都存在不确定性，都会影响到后续药品上市的时间。 转自：贝壳财经 ...

长春高新（000661.SZ）：儿科隐形赛道新突破，GenSci141开启第二增长曲线 核心观点 市场对长春高新的认知仍停留在"生长激素依赖者"，却忽视了公司在儿科罕见病领域的重磅炸弹布局。 GenSci141软膏作为全球首个针对儿童病理性小阴茎的First-in-class外用药物，近期已正式获批临床，标志着其距离 商业化更近一步。 不同于市场对存量激素业务 长春高新（000661.SZ）：儿科隐形赛道新突破，GenSci141开启第二增长曲线 核心观点 · 存量患者：中国3-12岁男性儿童存量约3.6万人。 · 年新增：每年新增病理性患儿约2100人。 市场对长春高新的认知仍停留在"生长激素依赖者"，却忽视了公司在儿科罕见病领域的重磅炸弹布局。 GenSci141软膏作为全球首个针对儿童病理性小阴茎的First-in-class外用药物，近期已正式获批临床，标志着其距离 商业化更近一步。 不同于市场对存量激素业务过度悲观的预期，我们认为：GenSci141不仅是管线的突破，更是公司商业模式的复 刻。 它具备"全球首创+罕见病刚需+儿科渠道复用+高定价权"四大核心要素，有望复刻生长激素的商业传奇。 经我们测 ...

Group 1: Automotive Industry - Stellantis, the global fourth-largest automotive manufacturer, reported a net loss of €22.3 billion (approximately ¥180.2 billion) for the year 2025, primarily due to €25.4 billion in extraordinary restructuring costs incurred in the second half of the year [1] - Despite the losses, Stellantis showed signs of recovery in the second half of 2025, with revenue growth and significantly improved cash flow compared to the first half [1] - The company's net revenue for 2025 was €153.5 billion, a slight decrease of 2% year-on-year, attributed to foreign exchange impacts and declining new car prices in the first half [1] Group 2: Pharmaceutical Industry - Changchun High-tech's subsidiary, JinSai Pharmaceutical, received approval for clinical trials of GenSci141 ointment, a drug aimed at treating male children's developmental disorders, marking a significant market opportunity as no similar products exist globally [3][4] - Following the announcement, Changchun High-tech's stock price surged over 12% within two days, reflecting strong market interest and potential for growth in the pharmaceutical sector [2] Group 3: Technology and Communication - WeChat launched a new feature allowing users to check how many chats a file has been used in, which does not duplicate storage space, addressing user concerns about storage management [6] - Meituan has applied for trademarks related to real estate, indicating a strategic move into property-related services [5] Group 4: Corporate Changes - Ctrip announced the resignation of its co-founder and president, Fan Min, along with board member Ji Qi, as part of a restructuring effort to enhance the board's professional diversity and strategic oversight capabilities [7][8] - ByteDance's valuation has risen to $550 billion, reflecting a 66% increase compared to last year's stock buyback valuation, indicating strong investor confidence in the company's growth potential [9]

Group 1 - China and the US are maintaining communication through the economic consultation mechanism, aiming for stable and sustainable development of bilateral trade relations [2] - German Chancellor Merz's visit to China resulted in over ten commercial agreements, emphasizing cooperation in AI and other advanced fields [3][51] - China has implemented export controls on Japan to prevent its militarization and nuclear ambitions, reflecting concerns over regional peace [4][52][53] Group 2 - The deployment of 11 US F-22 stealth fighters in Israel marks a significant military presence in the Middle East [5][54] - Indirect negotiations between the US and Iran have reportedly made significant progress, with further discussions scheduled [7][55] - China's AI model usage surged, surpassing the US for the first time, with a notable increase in model calls [8][56] Group 3 - New regulations for online food safety will take effect on June 1, requiring platforms to take responsibility for food safety throughout their operations [9][57] - The offshore RMB has appreciated significantly, breaking the 6.83 mark, indicating a strong upward trend in the currency [10][58] - Shanghai's gold recovery industry may soon require mandatory real-name registration to enhance security and traceability [11][59] Group 4 - Ctrip Group announced a change in leadership, with the resignation of its president and a significant increase in revenue for Q4 2025 [16][62] - The Guotou Ruijin silver fund compensation process has begun, with over 10,000 users engaging in the resolution process via an online platform [17][63] - The rumor regarding Sanzi Yang's successful backdoor listing has been officially denied, clarifying the company's current status [18][64] Group 5 - Nvidia reported record revenue for Q4 2026, driven by its data center business, which has seen substantial growth since the launch of ChatGPT [19][66] - Longcheng High-tech's new drug for treating boys' developmental issues has led to a significant increase in its stock price, reflecting market excitement [22][68] - The actual controller of Dongfang Fortune plans to donate a substantial amount of shares to Shanghai Jiao Tong University, highlighting corporate social responsibility [23][69]